TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00621660

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture was administered bilaterally to the standard antiemetic point2-4 pericardium six (PC6) located between the tendons of palmaris longus and flexor carpii radialis at two body-inches proximal of the wrist crease. Sharp needles, diameter 0.25 x length 40 millimetres, were inserted into a depth of a half body-inch. One body-inch (or a cun in traditional Chinese medicine context) is equivalent to the greatest width of the individual patients´ thumb at the distal phalanx, approximately one and a half centimetres or one American thumb. The needles were manipulated three times (at the start, middle and end of the treatment session) by twirling, thrusting and lifting until deqi occurred.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Sham acupuncture was administered bilaterally to a non-acupuncture point two body-inches proximal of PC6 with the telescopic Park sham device16, 0.30 x 40 millimetres (fully extended length). That needle looks identical with a real needle but is blunted and glides upwards into its handle instead of penetrating, which gives an illusion of penetration. The marking tubes hold the needles in place. The therapist gave an illusion of manipulation by turning the needle three times, each time for a couple of seconds until the needle touched the skin, but no deqi occurred. Except when placing and manipulating the sham needle, it was not pressed against the skin at all.
Study: NCT02132910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RESTORE Intervention
Study: NCT01378273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epo
Description: Enrollment will occur within 24 hours of birth. Study drug will be administered intravenously for the first 6 doses. Subjects in the Epo arm will then receive 400 U/kg/dose three times a week until they reach 32-6/7 weeks postmenstrual age. Control infants will receive sham injections.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
Study: NCT04216914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand outline
Description: A simple outline of a hand, to which the child tried to match their own hand on order to improve positioning.
Study: NCT04325984

Intervention type: DRUG
Intervention: Dexamethasone
Description: To the Dexamethasone group, at the moment of the induction of anaesthesia, dexamethasone 8 mg is administered.
Study: NCT02641483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical Rectal Stimulation
Description: Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
Study: NCT00076024

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 5 mg twice daily \[bid\] continuous dosing

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: Standard of care drug administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736 (axitinib)
Description: 5mg twice daily \[bid\] continuous dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Standard of care drug administration
Study: NCT00301821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epratuzumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT03718325

Intervention type: DEVICE
Group type: OTHER
Intervention: Burst-SCS
Description: The treatment arm used in the study is clinically-effective burst spinal cord stimulation (Burst-SCS). The device used to deliver Burst-SCS is the St. Jude Medical Invisible Trial System.

Intervention type: DEVICE
Group type: OTHER
Intervention: Burst-SCS
Description: The treatment arm used in the study is clinically-effective burst spinal cord stimulation (Burst-SCS). The device used to deliver Burst-SCS is the St. Jude Medical Invisible Trial System.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham SCS
Description: The placebo control arm used in the study is sham spinal cord stimulation (sham SCS). The device used to deliver sham SCS is the St. Jude Medical Invisible Trial System.

Intervention type: DEVICE
Group type: OTHER
Intervention: Sham SCS
Description: The placebo control arm used in the study is sham spinal cord stimulation (sham SCS). The device used to deliver sham SCS is the St. Jude Medical Invisible Trial System.
Study: NCT01273376

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RX-10100
Description: Extended-release tablet, taken twice daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10100
Description: Extended-release tablet, taken twice daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-10100
Description: Extended-release tablet, taken twice daily for 8 weeks
Study: NCT00267618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FHP Pain
Description: Evidence-based psychological and behavioural Intervention
Study: NCT01816841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluorescence imaging
Description: Undergo DVFE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluorescence imaging
Description: Undergo DVFE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Undergo scalpel biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Undergo scalpel biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: examination
Description: Undergo COE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: examination
Description: Undergo COE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparison of surgical margins by COE vs. DVFE
Description: Surgical margin determination using DVFE
Study: NCT00306202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. Once daily (QD), as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after end-of-treatment (EOT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose level 2 of 80 mg/m\^2, Escalated/Dose level 3 of 100 mg/m\^2, and Escalated/Dose level 4 of 120 mg/m\^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT.
Study: NCT02097537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine Chloride (SK-1211)
Study: NCT00882973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM
Description: Cremophor EL-free polymeric micelle of paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM
Description: Cremophor EL-free polymeric micelle of paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM
Description: Cremophor EL-free polymeric micelle of paclitaxel
Study: NCT00349427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosiglitazone 4 mg
Study: NCT01612728

Intervention type: OTHER
Group type: OTHER
Intervention: Women without Arthralgia
Description: For mild arthralgia, women will try the following interventions in the following order: 1) Weight-bearing exercise program, and 2) Glucosamine \& Chondroitin supplements. For women with mild to moderate arthralgia, they will try to the following interventions in this order: 1) Acupuncture, 2) Indomethacin twice daily as needed, 3) Switch to a different aromatase inhibitor, and 4) Switch to tamoxifen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Women with Arthralgia
Study: NCT02140632

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local methylprednisolone acetate and lidnocaine injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wrist splinting
Study: NCT03609151

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic hepatectomy (surgery)
Description: Patients receive laparoscopic hepatectomy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: Patients receive stereotactic body radiotherapy(SBRT)
Study: NCT03206073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg of durvalumab via intravenous (IV) infusion on Day 1 of each cycle until patients meet off treatment criteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg of durvalumab via intravenous (IV) infusion on Day 1 of each cycle until patients meet off treatment criteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg of durvalumab via intravenous (IV) infusion on Day 1 of each cycle until patients meet off treatment criteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg of durvalumab via intravenous (IV) infusion on Day 1 of each cycle until patients meet off treatment criteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 300 mg of tremelimumab via intravenous (IV) infusion on Day 1 of cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 300 mg of tremelimumab via intravenous (IV) infusion on Day 1 of cycle 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexa-Vec
Description: 3 x 10E\^8 plaque-forming unit (pfu) (Dose Level (DL) 1) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexa-Vec
Description: 3 x 10E\^8 plaque-forming unit (pfu) (Dose Level (DL) 1) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexa-Vec
Description: 1 x 10E\^9 pfu (DL 2) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pexa-Vec
Description: 1 x 10E\^9 pfu (DL 2) via intravenous (IV) infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.
Study: NCT03675737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered as an IV infusion on Day 1 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered as an IV infusion on Day 1 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered as an IV infusion on Day 1 Q3W
Study: NCT01272219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide 3.0 mg for 12 weeks (until week 68).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide 3.0 mg, subcutaneous (under the skin) injection once daily for 160 weeks.
Study: NCT03675737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Administered as a continuous IV infusion on Days 1-5 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Administered as a continuous IV infusion on Days 1-5 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Administered as an IV infusion on Day 1 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Administered as an IV infusion on Day 1 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Administered orally BID on Days 1 to 14 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: Administered orally BID on Days 1 to 14 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Pembrolizumab
Description: Administered as an IV infusion on Day 1 Q3W
Study: NCT00994487

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Energy Density Preload
Description: Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is high in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles
Study: NCT03078725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: oral hypoglycemic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: oral hypoglycemic agent
Study: NCT02273323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tea
Description: Single dose of black tea infusion containing approximately 400 mg flavonoids (expressed as gallic acid equivalents) with added sugar.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: tea flavour, colouring and sugar
Study: NCT03902405

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active CEASAR Intervention
Description: Healthy and stimulant-use related pictures will be presented on a computer screen. Using a joystick, participants will be trained to pull in pictures that are presented in portrait orientation, and push those presented horizontally. In the active experimental condition, pushed pictures will exclusively be stimulant-related pictures.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo CEASAR
Description: In the control condition, stimulant cues and healthy cues will be randomized and stimulant use-related pictures will be equally divided into push and pull conditions.
Study: NCT01209208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 9 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: 3 g per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 g per day
Study: NCT03037320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: comparison of coronally advanced flap and semilunar vestibular incision technique for root coverage in maxillary teeth

Intervention type: PROCEDURE
Group type: OTHER
Intervention: comparison of coronally advanced flap and semilunar vestibular incision technique for root coverage in maxillary teeth
Study: NCT02897635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Integrative Medicine Intervention
Study: NCT05913076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for first group
Description: The study involved the fabrication of occlusal-coverage bonded type RME devices utilizing Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy). Each patient in Group 1 (classical RME method) was instructed to open Hyrax screw twice a day for a week. At the end of the respective periods (1 week), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for second group
Description: The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 2. Each patient in Group 2 (3-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. At the end of the respective periods (3 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for third group
Description: The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 3. Each patient in Group 3 (5-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. The aforementioned screw open-close procedure was implemented over a period of five weeks. At the end of the respective periods (5 weeks), the screws were fixed with ligatures, and the patients were evaluated.~Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months.
Study: NCT04132752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivation
Description: Families were called via phone weekly and all questions were answered. Parents were motivated through phone.
Study: NCT04174885

Intervention type: PROCEDURE
Group type: OTHER
Intervention: epicardial ablation
Description: In general anesthesia and left lung ventilation, authors will access the right thorax by three working ports. However, a rigid video thoracoscopic camera with a direct optics will be used. Pericardium will be widely opened anterior to a phrenic nerve and transverse and oblique sinuses were dissected. An insertion of the ablation catheter will be a tricky part of the surgery with the first MW catheter, while no special introducer will be provided. Later RF devices will be equipped with a special flexible introducers, lately also with a magnetic tip and the positioning of the catheter around PVs became much safer and easier.~The correct position of catheter will be visualized by trans esophageal echocardiography before the ablation.